StockSelector.com
  Research, Select, & Monitor Saturday, November 18, 2017 5:11:41 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Johnson & Johnson$138.00($.87)(.63%)

  Quote | Ranking | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

 Johnson & Johnson Reports 2014 Fourth-Quarter and Full-Year Results:
   Tuesday, January 20, 2015 7:45:00 AM ET

Johnson & Johnson (JNJ ) today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%. International sales decreased 6.7%, reflecting operational growth of 1.2% and a negative currency impact of 7.9%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 6.7%, domestic sales increased 10.7% and international sales increased 3.6%.*

Worldwide sales for the full-year 2014 were $74.3 billion, an increase of 4.2% versus 2013. Operational results increased 6.1% and the negative impact of currency was 1.9%. Domestic sales increased 9.0%. International sales increased 0.4%, reflecting operational growth of 3.7% and a negative currency impact of 3.3%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 8.0%, domestic sales increased 11.6% and international sales increased 5.1%.*

Net earnings and diluted earnings per share for the fourth quarter of 2014 were $2.5 billion and $0.89, respectively. Fourth-quarter 2014 net earnings included a charge for after-tax special items of approximately $1.1 billion, primarily related to an increase in the litigation accrual, integration costs related to the acquisition of Synthes, Inc., and an in-process research and development charge. Fourth-quarter 2013 net earnings included a net charge for after-tax special items of $42 million as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items, net earnings for the current quarter were $3.6 billion and diluted earnings per share were $1.27, representing increases of 1.4% and 2.4%, respectively, as compared to the same period in 2013.*

Net earnings and diluted earnings per share for the full-year 2014 were $16.3 billion and $5.70, respectively. Full-year net earnings included a net charge for after-tax special items of $0.8 billion in 2014 and $2.0 billion in 2013 as detailed in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items in both periods, net earnings for the full-year of 2014 were $17.1 billion and diluted earnings per share were $5.97, representing increases of 7.7% and 8.2%, respectively, as compared with the full year of 2013.*

"2014 was a strong year for Johnson & Johnson, as we delivered solid financial results while continuing to make investments to accelerate growth for the long term. We have built significant momentum in our Pharmaceutical business, are realizing the benefits of innovation, scale and breadth in our Medical Devices business and are continuing our market leadership with iconic brands in our Consumer business," said Alex Gorsky, Chairman and Chief Executive Officer. "I am proud of our exceptional Johnson & Johnson colleagues who make our success possible with their commitment to advancing health and well-being for patients and consumers around the world."

The Company announced adjusted earnings guidance for full-year 2015 of $6.12 to $6.27 per share. Beginning in 2015, adjusted earnings excludes after-tax intangible amortization expense in addition to special items. After-tax intangible amortization expense for 2014 was approximately $0.42 per share and for 2015 is anticipated to be approximately $0.32 per share.

Worldwide Consumer sales of $14.5 billion for the full-year 2014 represented a decrease of 1.4% versus the prior year, consisting of an operational increase of 1.0% and a negative impact from currency of 2.4%. Domestic sales decreased 1.3%; international sales decreased 1.4%, which reflected an operational increase of 2.3% and a negative currency impact of 3.7%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 2.8%, domestic sales increased 3.1% and international sales increased 2.6%.*

Positive contributors to operational results were sales of TYLENOL? and MOTRIN? analgesics and ZYRTEC? allergy over-the-counter products; AVEENO? and NEUTROGENA? skin care products; and LISTERINE? oral care products.

Worldwide Pharmaceutical sales of $32.3 billion for the full-year 2014 represented an increase of 14.9% versus the prior year with operational growth of 16.5% and a negative impact from currency of 1.6%. Domestic sales increased 25.0%; international sales increased 5.0%, which reflected an operational increase of 8.3% and a negative currency impact of 3.3%.

The strong sales results were driven by new products and the strength of our core products. New products include OLYSIO?/SOVRIAD? (simeprevir), for combination treatment of chronic hepatitis C in adult patients; XARELTO? (rivaroxaban), an oral anticoagulant; ZYTIGA? (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA? (canagliflozin), for the treatment of adults with type 2 diabetes; and IMBRUVICA? (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers.

Additional contributors to operational sales growth were STELARA? (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; INVEGA? SUSTENNA?/XEPLION? (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; SIMPONI?/SIMPONI ARIA? (golimumab) and REMICADE? (infliximab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases.

During the quarter, the U.S. Food and Drug Administration (FDA) granted approval for the supplemental New Drug Applications (sNDAs) for INVEGA? SUSTENNA? (paliperidone palmitate) to treat schizoaffective disorder as either monotherapy or adjunctive therapy. The European Commission approved IMBRUVICA? (ibrutinib) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma and adult patients with chronic lymphocytic leukemia who have received at least one prior therapy, or in first-line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. The European Commission also approved REZOLSTA? (darunavir/cobicistat) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 infection in adults aged 18 years or older. In addition, VELCADE? (bortezomib) received a positive opinion from the European Committee for Medicinal Products for use in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Two New Drug Applications (NDAs) were submitted to the FDA for regulatory approval during the quarter. These included an NDA for three-month atypical antipsychotic paliperidone palmitate as a treatment for schizophrenia in adults as well as an NDA for YONDELIS? (trabectedin) for the treatment of patients with advanced soft tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline. Also, a supplemental NDA was submitted to the FDA and a Type II variation application was submitted to the European Medicines Agency (EMA) for an additional indication of IMBRUVICA? (ibrutinib) for the treatment of patients with Waldenstrom’s macroglobulinemia, a rare type of B-cell lymphoma.

In addition, the acquisition of Alios BioPharma, Inc., a privately-held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, was completed. In January, a definitive agreement was announced to divest the U.S. license rights to NUCYNTA? (tapentadol), NUCYNTA? ER (tapentadol extended-release tablets), and NUCYNTA? (tapentadol) oral solution for approximately $1.05 billion. The transaction is expected to close in the second quarter, subject to customary closing conditions and completion of financing.

Worldwide Medical Devices sales of $27.5 billion for the full-year 2014 represented a decrease of 3.4% versus the prior year consisting of an operational decrease of 1.6% and a negative currency impact of 1.8%. Domestic sales decreased 4.3%; international sales decreased 2.7%, which reflected an operational increase of 0.5% and a negative currency impact of 3.2%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.6%, domestic sales decreased 0.6% and international sales increased 3.5%.* The divestiture of the Ortho-Clinical Diagnostics business was completed in June.

Primary contributors to operational growth were our broad portfolio of Orthopaedic products; Biosense Webster’s electrophysiology products in the Cardiovascular Care business; and biosurgicals and international sales of energy products in the Specialty Surgery business.

During the quarter, the FDA approved the Animas? Vibe(TM) insulin pump and Continuous Glucose Monitoring system for the management of insulin-requiring diabetes in adults ages 18 and older.

About Johnson & Johnson Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,500 employees at more than 265 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Operational sales growth excluding the net impact of acquisitions and divestitures as well as net earnings and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can be found on the Company’s website at www.investor.jnj.com.

NOTE TO INVESTORS

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new and existing products; impact of business combinations and divestitures; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; the impact of patent expirations; significant adverse litigation or government action, including related to product liability claims; changes to laws and regulations, including domestic and foreign health care reforms; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; financial instability of international economies and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)   FOURTH QUARTER                                     TWELVE MONTHS
                                                      Percent Change                                     Percent Change
                                   2014       2013    Total     Operations  Currency  2014       2013    Total    Operations  Currency
Sales to customers by
segment of business
Consumer
U.S.                               $   1,294  1,263   2.5    %  2.5         -         $   5,096  5,162   (1.3) %  (1.3)       -
International                      2,312      2,490   (7.1)     0.1         (7.2)     9,400      9,535   (1.4)    2.3         (3.7)
                                   3,606      3,753   (3.9)     0.9         (4.8)     14,496     14,697  (1.4)    1.0         (2.4)
Pharmaceutical
U.S.                               4,356      3,551   22.7      22.7        -         17,432     13,948  25.0     25.0        -
International                      3,643      3,745   (2.7)     5.8         (8.5)     14,881     14,177  5.0      8.3         (3.3)
                                   7,999      7,296   9.6       13.9        (4.3)     32,313     28,125  14.9     16.5        (1.6)
Medical Devices
U.S.                               2,954      3,200   (7.7)     (7.7)       -         12,254     12,800  (4.3)    (4.3)       -
International                      3,695      4,106   (10.0)    (2.3)       (7.7)     15,268     15,690  (2.7)    0.5         (3.2)
                                   6,649      7,306   (9.0)     (4.7)       (4.3)     27,522     28,490  (3.4)    (1.6)       (1.8)
U.S.                               8,604      8,014   7.4       7.4         -         34,782     31,910  9.0      9.0         -
International                      9,650      10,341  (6.7)     1.2         (7.9)     39,549     39,402  0.4      3.7         (3.3)
Worldwide                          $ 18,254   18,355  (0.6)  %  3.9         (4.5)     $ 74,331   71,312  4.2   %  6.1         (1.9)
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)   FOURTH QUARTER                                    TWELVE MONTHS
                                                      Percent Change                                   Percent Change
                                   2014       2013    Total    Operations  Currency  2014      2013    Total    Operations  Currency
Sales to customers by
geographic area
U.S.                               $   8,604  8,014   7.4   %  7.4         -         $ 34,782  31,910  9.0   %  9.0         -
Europe                             4,560      4,968   (8.2)    0.6         (8.8)     18,947    18,599  1.9      2.6         (0.7)
Western Hemisphere excluding U.S.  1,782      1,891   (5.8)    3.9         (9.7)     7,160     7,421   (3.5)    5.2         (8.7)
Asia-Pacific, Africa               3,308      3,482   (5.0)    0.6         (5.6)     13,442    13,382  0.4      4.4         (4.0)
International                      9,650      10,341  (6.7)    1.2         (7.9)     39,549    39,402  0.4      3.7         (3.3)
Worldwide                          $ 18,254   18,355  (0.6) %  3.9         (4.5)     $ 74,331  71,312  4.2   %  6.1         (1.9)
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)                FOURTH QUARTER
                                                                 2014                    2013                    Percent
                                                                               Percent                 Percent   Increase
                                                                 Amount        to Sales  Amount        to Sales  (Decrease)
Sales to customers                                               $  18,254     100.0     $  18,355     100.0     (0.6)
Cost of products sold                                            5,853         32.1      5,955         32.5      (1.7)
Selling, marketing and administrative expenses                   5,822         31.9      5,917         32.2      (1.6)
Research and development expense                                 2,635         14.4      2,411         13.1      9.3
In-process research and development                              156           0.8       338           1.9
Interest (income) expense, net                                   122           0.7       116           0.6
Other (income) expense, net                                      963           5.3       868           4.7
Earnings before provision for taxes on income                    2,703         14.8      2,750         15.0      (1.7)
Provision for/(Benefit from) taxes on income                     182           1.0       (769)         (4.2)
Net earnings                                                     $    2,521    13.8      $    3,519    19.2      (28.4)
Net earnings per share (Diluted)                                 $      0.89             $      1.23             (27.6)
Average shares outstanding (Diluted)                             2,845.3                 2,872.0
Effective tax rate                                               6.7         %           (28.0)      %
Adjusted earnings before provision for taxes and net earnings(1)
Earnings before provision for taxes on income                    $    3,925    21.5      $    3,909    21.3      0.4
Net earnings                                                     $    3,612    19.8      $    3,561    19.4      1.4
Net earnings per share (Diluted)                                 $      1.27             $      1.24             2.4
Effective tax rate                                               8.0         %           8.9         %
(1)See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)                 TWELVE MONTHS
                                                                  2014                    2013                    Percent
                                                                                Percent                 Percent   Increase
                                                                  Amount        to Sales  Amount        to Sales  (Decrease)
Sales to customers                                                $  74,331     100.0     $  71,312     100.0     4.2
Cost of products sold                                             22,746        30.6      22,342        31.3      1.8
Selling, marketing and administrative expenses                    21,954        29.5      21,830        30.6      0.6
Research and development expense                                  8,494         11.4      8,183         11.5      3.8
In-process research and development                               178           0.3       580           0.8
Interest (income) expense, net                                    466           0.6       408           0.6
Other (income) expense, net                                       (70)          (0.1)     2,498         3.5
Earnings before provision for taxes on income                     20,563        27.7      15,471        21.7      32.9
Provision for taxes on income                                     4,240         5.7       1,640         2.3
Net earnings                                                      $  16,323     22.0      $  13,831     19.4      18.0
Net earnings per share (Diluted)                                  $      5.70             $      4.81             18.5
Average shares outstanding (Diluted)                              2,863.9                 2,877.0
Effective tax rate                                                20.6        %           10.6        %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income                     $  21,195     28.5      $  19,169     26.9      10.6
Net earnings                                                      $  17,105     23.0      $  15,876     22.3      7.7
Net earnings per share (Diluted)                                  $      5.97             $      5.52             8.2
Effective tax rate                                                19.3        %           17.2        %
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
                                                                    Fourth Quarter                  % Incr. /    Twelve Months           % Incr. /
(Dollars in Millions Except Per Share Data)                         2014                    2013    (Decr.)      2014            2013    (Decr.)
Earnings before provision for taxes on income - as reported         $    2,703              2,750   (1.7)     %  $ 20,563        15,471  32.9      %
Ortho-Clinical Diagnostics divestiture net (gain)/expense           49                      -                    (1,899)         -
Litigation expenses                                                 692                     506                  1,253           2,282
Synthes integration/transaction costs                               325                     181                  754             683
Additional year of Branded Prescription Drug Fee                    -                       -                    220             -
In-process research and development                                 156                     338                  178             580
DePuy ASRTMHip program                                              -                       134                  126             251
Other                                                               -                       -                    -               (98)
Earnings before provision for taxes on income - as adjusted         $    3,925              3,909   0.4       %  $ 21,195        19,169  10.6      %
Net Earnings - as reported                                          $    2,521              3,519   (28.4)    %  $ 16,323        13,831  18.0      %
Ortho-Clinical Diagnostics divestiture net (gain)/expense           87                      -                    (1,062)         -
Litigation expenses                                                 652                     227                  1,225      (1)  1,646
Synthes integration/transaction costs                               237                     110                  555             483
Additional year of Branded Prescription Drug Fee                    -                       -                    220             -
In-process research and development                                 115                     294                  131             462
DePuy ASRTMHip program                                              -                       118                  111             240
Tax benefit associated with Conor Medsystems                        -                       -                    (398)           -
Scios tax benefit                                                   -                       (707)                -               (707)
Other                                                               -                       -                    -               (79)
Net Earnings  - as adjusted                                         $    3,612              3,561   1.4       %  $ 17,105        15,876  7.7       %
Diluted Net Earnings per share  - as reported                       $     0.89              1.23    (27.6)    %  $     5.70      4.81    18.5      %
Ortho-Clinical Diagnostics divestiture net (gain)/expense           0.03                    -                    (0.37)          -
Litigation expenses                                                 0.23                    0.08                 0.43            0.57
Synthes integration/transaction costs                               0.08                    0.04                 0.19            0.17
Additional year of Branded Prescription Drug Fee                    -                       -                    0.08            -
In-process research and development                                 0.04                    0.10                 0.04            0.16
DePuy ASRTMHip program                                              -                       0.04                 0.04            0.08
Tax benefit associated with Conor Medsystems                        -                       -                    (0.14)          -
Scios Tax Benefit                                                   -                       (0.25)               -               (0.25)
Other                                                               -                       -                    -               (0.02)
Diluted Net Earnings per share  - as adjusted                       $     1.27              1.24    2.4       %  $     5.97      5.52    8.2       %
(1) Includes adjustment to deferred tax asset related to deductibility by tax jurisdiction
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions and Divestitures
FOURTH QUARTER 2014 ACTUAL vs. 2013 ACTUAL
Segments
                                                                    Operational % (1)
                                                                    Consumer  Pharmaceutical Medical Devices  Total
WW As Reported:                                                     0.9%      13.9%          (4.7)%           3.9%
U.S.                                                                2.5%      22.7%          (7.7)%           7.4%
International                                                       0.1%      5.8%           (2.3)%           1.2%
Women’s Health
Sanitary Protection                                                 0.5                                       0.1
U.S.                                                                1.4                                       0.2
International                                                       0.1                                       0.0
Women’s Health
K-Y ?                                                               0.5                                       0.2
U.S.                                                                1.0                                       0.2
International                                                       0.3                                       0.1
Diagnostics
Ortho-Clinical Diagnostics                                                                   6.2              2.5
U.S.                                                                                         6.7              2.9
International                                                                                5.8              2.3
All Other Acquisitions and Divestitures                             0.2                                       0.0
U.S.                                                                0.0                                       0.0
International                                                       0.2                                       0.0
WW Ops excluding Acquisitions and Divestitures                      2.1%      13.9%          1.5%             6.7%
U.S.                                                                4.9%      22.7%          (1.0)%           10.7%
International                                                       0.7%      5.8%           3.5%             3.6%
(1)Operational growth excludes the effect of translational currency
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions and Divestitures
TWELVE MONTHS 2014 ACTUAL vs. 2013 ACTUAL
Segments
                                                                     Operational % (1)
                                                                     Consumer  Pharmaceutical Medical Devices  Total
WW As Reported:                                                      1.0%      16.5%          (1.6)%           6.1%
U.S.                                                                 (1.3)%    25.0%          (4.3)%           9.0%
International                                                        2.3%      8.3%           0.5%             3.7%
Women’s Health
Sanitary Protection                                                  1.4                                       0.3
U.S.                                                                 3.8                                       0.6
International                                                        0.1                                       0.0
Women’s Health
K-Y ?                                                                0.3                                       0.1
U.S.                                                                 0.6                                       0.1
International                                                        0.1                                       0.0
Diagnostics
Ortho-Clinical Diagnostics                                                                    3.2              1.4
U.S.                                                                                          3.7              1.8
International                                                                                 3.0              1.2
All Other Acquisitions and Divestitures                              0.1       0.1                             0.1
U.S.                                                                 0.0       0.1                             0.1
International                                                        0.1       0.1                             0.2
WW Ops excluding Acquisitions and Divestitures                       2.8%      16.6%          1.6%             8.0%
U.S.                                                                 3.1%      25.1%          (0.6)%           11.6%
International                                                        2.6%      8.4%           3.5%             5.1%
(1)Operational growth excludes the effect of translational currency
                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                 FOURTH QUARTER                                               TWELVE MONTHS
                                                           % Change                                                      % Change
                                    2014             2013  Reported Operational (1) Currency  2014                2013   Reported Operational (1) Currency
CONSUMER SEGMENT (2)
BABY CARE
US                                  $            96  105   -8.6%    -8.6%           -         $              407  413    -1.5%    -1.5%           -
Intl                                428              480   -10.8%   -4.8%           -6.0%     1,832               1,882  -2.7%    1.8%            -4.5%
WW                                  524              585   -10.4%   -5.5%           -4.9%     2,239               2,295  -2.4%    1.3%            -3.7%
ORAL CARE
US                                  150              153   -2.0%    -2.0%           -         600                 602    -0.3%    -0.3%           -
Intl                                264              265   -0.4%    6.1%            -6.5%     1,047               1,020  2.6%     5.9%            -3.3%
WW                                  414              418   -1.0%    3.1%            -4.1%     1,647               1,622  1.5%     3.6%            -2.1%
OTC
US                                  362              332   9.0%     9.0%            -         1,357               1,286  5.5%     5.5%            -
Intl                                711              747   -4.8%    3.6%            -8.4%     2,749               2,742  0.3%     3.7%            -3.4%
WW                                  1,073            1,079 -0.6%    5.2%            -5.8%     4,106               4,028  1.9%     4.2%            -2.3%
SKIN CARE
US                                  471              432   9.0%     9.0%            -         1,834               1,752  4.7%     4.7%            -
Intl                                485              538   -9.9%    -3.7%           -6.2%     1,924               1,952  -1.4%    1.2%            -2.6%
WW                                  956              970   -1.4%    2.0%            -3.4%     3,758               3,704  1.5%     2.9%            -1.4%
WOMEN’S HEALTH
US                                  7                38    -81.6%   -81.6%          -         50                  280    -82.1%   -82.1%          -
Intl                                301              310   -2.9%    6.0%            -8.9%     1,252               1,288  -2.8%    2.6%            -5.4%
WW                                  308              348   -11.5%   -3.6%           -7.9%     1,302               1,568  -17.0%   -12.6%          -4.4%
WOUND CARE/OTHER
US                                  208              203   2.5%     2.5%            -         848                 829    2.3%     2.3%            -
Intl                                123              150   -18.0%   -11.6%          -6.4%     596                 651    -8.4%    -6.3%           -2.1%
WW                                  331              353   -6.2%    -3.5%           -2.7%     1,444               1,480  -2.4%    -1.5%           -0.9%
TOTAL CONSUMER
US                                  1,294            1,263 2.5%     2.5%            -         5,096               5,162  -1.3%    -1.3%           -
Intl                                2,312            2,490 -7.1%    0.1%            -7.2%     9,400               9,535  -1.4%    2.3%            -3.7%
WW                                  $       3,606    3,753 -3.9%    0.9%            -4.8%     $         14,496    14,697 -1.4%    1.0%            -2.4%
See footnotes at end of schedule
                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                 FOURTH QUARTER                                               TWELVE MONTHS
                                                           % Change                                                      % Change
                                    2014             2013  Reported Operational (1) Currency  2014                2013   Reported Operational (1) Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US                                  $       1,816    1,726 5.2%     5.2%            -         $           7,111   6,591  7.9%     7.9%            -
Intl                                762              676   12.7%    22.2%           -9.5%     3,082               2,599  18.6%    23.3%           -4.7%
WW                                  2,578            2,402 7.3%     10.0%           -2.7%     10,193              9,190  10.9%    12.2%           -1.3%
REMICADE
US                                  $       1,052    982   7.1%     7.1%            -         4,155               3,891  6.8%     6.8%            -
US Exports (4)                      244              367   -33.5%   -33.5%          -         1,078               1,339  -19.5%   -19.5%          -
Intl                                376              363   3.6%     12.6%           -9.0%     1,635               1,443  13.3%    19.0%           -5.7%
WW                                  1,672            1,712 -2.3%    -0.4%           -1.9%     6,868               6,673  2.9%     4.1%            -1.2%
SIMPONI/SIMPONI ARIA
US                                  164              112   46.4%    46.4%           -         544                 404    34.7%    34.7%           -
Intl                                182              142   28.2%    39.0%           -10.8%    643                 528    21.8%    26.4%           -4.6%
WW                                  346              254   36.2%    42.2%           -6.0%     1,187               932    27.4%    30.0%           -2.6%
STELARA
US                                  356              265   34.3%    34.3%           -         1,334               957    39.4%    39.4%           -
Intl                                189              152   24.3%    34.3%           -10.0%    738                 547    34.9%    37.3%           -2.4%
WW                                  545              417   30.7%    34.4%           -3.7%     2,072               1,504  37.8%    38.7%           -0.9%
OTHER IMMUNOLOGY
US                                  -                -     -        -               -         -                   -      -        -               -
Intl                                15               19    -21.1%   -15.9%          -5.2%     66                  81     -18.5%   -14.3%          -4.2%
WW                                  15               19    -21.1%   -15.9%          -5.2%     66                  81     -18.5%   -14.3%          -4.2%
INFECTIOUS DISEASES
US                                  564              302   86.8%    86.8%           -         3,112               1,077  *        *               -
Intl                                512              642   -20.2%   -12.1%          -8.1%     2,487               2,473  0.6%     2.5%            -1.9%
WW                                  1,076            944   14.0%    19.5%           -5.5%     5,599               3,550  57.7%    58.6%           -0.9%
EDURANT
US                                  6                5     20.0%    20.0%           -         24                  15     60.0%    60.0%           -
Intl                                84               68    23.5%    33.8%           -10.3%    341                 221    54.3%    54.3%           0.0%
WW                                  90               73    23.3%    32.9%           -9.6%     365                 236    54.7%    54.7%           0.0%
INCIVO
US                                  -                -     -        -               -         -                   -      -        -               -
Intl                                5                107   -95.3%   -90.7%          -4.6%     226                 517    -56.3%   -55.0%          -1.3%
WW                                  5                107   -95.3%   -90.7%          -4.6%     226                 517    -56.3%   -55.0%          -1.3%
OLYSIO/SOVRIAD
US                                  256              13    *        *               -         1,943               13     *        *               -
Intl                                65               10    *        *               -12.5%    359                 10     *        *               -2.3%
WW                                  321              23    *        *               -2.5%     2,302               23     *        *               -0.4%
PREZISTA
US                                  243              229   6.1%     6.1%            -         930                 807    15.2%    15.2%           -
Intl                                205              232   -11.6%   -3.5%           -8.1%     901                 866    4.0%     5.9%            -1.9%
WW                                  448              461   -2.8%    1.3%            -4.1%     1,831               1,673  9.4%     10.4%           -1.0%
OTHER INFECTIOUS DISEASES
US                                  59               55    7.3%     7.3%            -         215                 242    -11.2%   -11.2%          -
Intl                                153              225   -32.0%   -26.1%          -5.9%     660                 859    -23.2%   -21.2%          -2.0%
WW                                  212              280   -24.3%   -19.6%          -4.7%     875                 1,101  -20.5%   -18.9%          -1.6%
                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                 FOURTH QUARTER                                               TWELVE MONTHS
                                                           % Change                                                      % Change
                                    2014             2013  Reported Operational (1) Currency  2014                2013   Reported Operational (1) Currency
NEUROSCIENCE
US                                  645              611   5.6%     5.6%            -         2,452               2,584  -5.1%    -5.1%           -
Intl                                1,006            1,040 -3.3%    5.1%            -8.4%     4,035               4,083  -1.2%    2.2%            -3.4%
WW                                  1,651            1,651 0.0%     5.3%            -5.3%     6,487               6,667  -2.7%    -0.6%           -2.1%
CONCERTA/METHYLPHENIDATE
US                                  55               46    19.6%    19.6%           -         152                 308    -50.6%   -50.6%          -
Intl                                114              123   -7.3%    0.5%            -7.8%     447                 474    -5.7%    -1.6%           -4.1%
WW                                  169              169   0.0%     5.7%            -5.7%     599                 782    -23.4%   -20.9%          -2.5%
INVEGA
US                                  96               87    10.3%    10.3%           -         360                 316    13.9%    13.9%           -
Intl                                65               67    -3.0%    7.0%            -10.0%    280                 267    4.9%     8.7%            -3.8%
WW                                  161              154   4.5%     8.9%            -4.4%     640                 583    9.8%     11.5%           -1.7%
INVEGA SUSTENNA/ XEPLION
US                                  226              188   20.2%    20.2%           -         825                 690    19.6%    19.6%           -
Intl                                192              162   18.5%    27.8%           -9.3%     763                 558    36.7%    39.1%           -2.4%
WW                                  418              350   19.4%    23.7%           -4.3%     1,588               1,248  27.2%    28.3%           -1.1%
RISPERDAL CONSTA
US                                  104              113   -8.0%    -8.0%           -         427                 440    -3.0%    -3.0%           -
Intl                                190              208   -8.7%    -0.5%           -8.2%     763                 878    -13.1%   -10.9%          -2.2%
WW                                  294              321   -8.4%    -3.1%           -5.3%     1,190               1,318  -9.7%    -8.2%           -1.5%
OTHER NEUROSCIENCE
US                                  164              177   -7.3%    -7.3%           -         688                 830    -17.1%   -17.1%          -
Intl                                445              480   -7.3%    0.8%            -8.1%     1,782               1,906  -6.5%    -2.4%           -4.1%
WW                                  609              657   -7.3%    -1.4%           -5.9%     2,470               2,736  -9.7%    -6.9%           -2.8%
ONCOLOGY
US                                  334              216   54.6%    54.6%           -         1,157               848    36.4%    36.4%           -
Intl                                878              897   -2.1%    6.7%            -8.8%     3,300               2,925  12.8%    16.0%           -3.2%
WW                                  1,212            1,113 8.9%     16.0%           -7.1%     4,457               3,773  18.1%    20.6%           -2.5%
VELCADE
US                                  -                -     -        -               -         -                   -      -        -               -
Intl                                418              524   -20.2%   -12.1%          -8.1%     1,618               1,660  -2.5%    1.1%            -3.6%
WW                                  418              524   -20.2%   -12.1%          -8.1%     1,618               1,660  -2.5%    1.1%            -3.6%
ZYTIGA
US                                  255              211   20.9%    20.9%           -         971                 750    29.5%    29.5%           -
Intl                                340              284   19.7%    29.9%           -10.2%    1,266               948    33.5%    36.1%           -2.6%
WW                                  595              495   20.2%    26.0%           -5.8%     2,237               1,698  31.7%    33.1%           -1.4%
OTHER ONCOLOGY
US                                  79               5     *        *               -         186                 98     89.8%    89.8%           -
Intl                                120              89    34.8%    43.9%           -9.1%     416                 317    31.2%    34.2%           -3.0%
WW                                  199              94    *        *               -8.6%     602                 415    45.1%    47.4%           -2.3%
                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                 FOURTH QUARTER                                               TWELVE MONTHS
                                                           % Change                                                      % Change
                                    2014             2013  Reported Operational (1) Currency  2014                2013   Reported Operational (1) Currency
TOTAL OTHER
US                                  997              696   43.2%    43.2%           -         3,600               2,848  26.4%    26.4%           -
Intl                                485              490   -1.0%    6.0%            -7.0%     1,977               2,097  -5.7%    -3.4%           -2.3%
WW                                  1,482            1,186 25.0%    27.9%           -2.9%     5,577               4,945  12.8%    13.8%           -1.0%
PROCRIT/EPREX
US                                  177              168   5.4%     5.4%            -         715                 795    -10.1%   -10.1%          -
Intl                                125              139   -10.1%   -3.2%           -6.9%     523                 569    -8.1%    -6.2%           -1.9%
WW                                                         302                   307             -1.6%           1.5%            -3.1%     1,238               1,364  -9.2%    -8.4%           -0.8%
XARELTO
US                                                         428                   271             57.9%           57.9%           -         1,522               864    76.2%    76.2%           -
Intl                                                       -                     -               -               -               -         -                   -      -        -               -
WW                                                         428                   271             57.9%           57.9%           -         1,522               864    76.2%    76.2%           -
OTHER
US                                                         392                   257             52.5%           52.5%           -         1,363               1,189  14.6%    14.6%           -
Intl                                                       360                   351             2.6%            9.6%            -7.0%     1,454               1,528  -4.8%    -2.4%           -2.4%
WW                                                         752                   608             23.7%           27.7%           -4.0%     2,817               2,717  3.7%     5.0%            -1.3%
TOTAL PHARMACEUTICAL
US                                                         4,356                 3,551           22.7%           22.7%           -         17,432              13,948 25.0%    25.0%           -
Intl                                                       3,643                 3,745           -2.7%           5.8%            -8.5%     14,881              14,177 5.0%     8.3%            -3.3%
WW                                                         $       7,999         7,296           9.6%            13.9%           -4.3%     $         32,313    28,125 14.9%    16.5%           -1.6%
See footnotes at end of schedule
                                                           REPORTED SALES vs. PRIOR PERIOD ($MM)
                                 FOURTH QUARTER                                                                                            TWELVE MONTHS
                                                                                                 % Change                                                             % Change
                                                           2014                  2013            Reported        Operational (1) Currency  2014                2013   Reported Operational (1) Currency
MEDICAL DEVICES (2) (3) (7)
CARDIOVASCULAR CARE
US                                                         $          222        210             5.7%            5.7%            -         $              862  808    6.7%     6.7%            -
Intl                                                       336                   324             3.7%            12.4%           -8.7%     1,346               1,269  6.1%     9.4%            -3.3%
WW                                                         558                   534             4.5%            9.8%            -5.3%     2,208               2,077  6.3%     8.3%            -2.0%
DIABETES CARE
US                                                         206                   219             -5.9%           -5.9%           -         864                 998    -13.4%   -13.4%          -
Intl                                                       308                   344             -10.5%          -1.5%           -9.0%     1,278               1,311  -2.5%    0.8%            -3.3%
WW                                                         514                   563             -8.7%           -3.2%           -5.5%     2,142               2,309  -7.2%    -5.3%           -1.9%
DIAGNOSTICS (5)
US                                                         -                     215             **              **              -         456                 926    -50.8%   -50.8%          -
Intl                                                       14                    251             -94.4%          -90.5%          -3.9%     506                 959    -47.2%   -44.9%          -2.3%
WW                                                         14                    466             -97.0%          -94.9%          -2.1%     962                 1,885  -49.0%   -47.8%          -1.2%
ORTHOPAEDICS
US                                                         1,339                 1,307           2.4%            2.4%            -         5,197               5,074  2.4%     2.4%            -
Intl                                                       1,102                 1,149           -4.1%           3.3%            -7.4%     4,478               4,435  1.0%     3.5%            -2.5%
WW                                                         2,441                 2,456           -0.6%           2.8%            -3.4%     9,675               9,509  1.7%     2.9%            -1.2%
SPECIALTY SURGERY/OTHER (6)
US                                                         425                   422             0.7%            0.7%            -         1,679               1,664  0.9%     0.9%            -
Intl                                                       479                   507             -5.5%           2.1%            -7.6%     1,862               1,840  1.2%     4.9%            -3.7%
WW                                                         904                   929             -2.7%           1.5%            -4.2%     3,541               3,504  1.1%     3.0%            -1.9%
SURGICAL CARE
US                                                         567                   599             -5.3%           -5.3%           -         2,221               2,294  -3.2%    -3.2%           -
Intl                                                       1,005                 1,040           -3.4%           4.0%            -7.4%     3,955               3,975  -0.5%    2.6%            -3.1%
WW                                                         1,572                 1,639           -4.1%           0.6%            -4.7%     6,176               6,269  -1.5%    0.5%            -2.0%
VISION CARE
US                                                         195                   228             -14.5%          -14.5%          -         975                 1,036  -5.9%    -5.9%           -
Intl                                                       451                   491             -8.1%           1.7%            -9.8%     1,843               1,901  -3.1%    1.7%            -4.8%
WW                                                         646                   719             -10.2%          -3.5%           -6.7%     2,818               2,937  -4.1%    -1.0%           -3.1%
TOTAL MEDICAL DEVICES
US                                                         2,954                 3,200           -7.7%           -7.7%           -         12,254              12,800 -4.3%    -4.3%           -
Intl                                                       3,695                 4,106           -10.0%          -2.3%           -7.7%     15,268              15,690 -2.7%    0.5%            -3.2%
WW                                                         $       6,649         7,306           -9.0%           -4.7%           -4.3%     $         27,522    28,490 -3.4%    -1.6%           -1.8%
* Percentage greater than 100%
** Not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Prior year amounts have been reclassified to conform to current year product disclosure
(4) Reported as U.S. sales
(5) Reflects Diagnostics divestiture June 30, 2014
(6) Infection Prevention now reflected in Specialty Surgery/Other, previously reported independently
(7) Previously referred to as  Medical Devices and Diagnostics

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2014-fourth-quarter-and-full-year-results-300022758.html

SOURCE Johnson & Johnson

http://rt.prnewswire.com/rt.gif?NewsItemId=NY11262&Transmission_Id=201501200745PR_NEWS_USPR_____NY11262&DateId=20150120



Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2017 StockSelector.com. All rights reserved.